Kyverna Therapeutics secures $150 million loan facility from Oxford Finance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance
November 3, 2025 8:00 AM ESTInitial funding of $25 million from the first of four tranchesÂ
Facility strengthens Kyvernas financial flexibility, further supporting advancement of its late-stage indications in generalized myasthenia gravis (gMG) and stiff person syndrome (SPS), while also accelerating pre-launch activities
Topline data readout of registrational Phase 2 SPS trial now expected in early 2026; narrowed from previous guidance of first half 2026
EMERYVILLE, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX) (Kyverna), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune... More
